🔗 Share this article

While America continues making sweeping adjustments to its immunization recommendations, an unexpected name appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by casting doubt on coronavirus vaccinations throughout the global health crisis and has zeroed in on potential deaths following Covid immunization in her short position at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Vaccine Program

Public health authorities had intended to reveal major revisions to the pediatric vaccine schedule in December, bringing the US with the Danish immunization schedule, according to reports – a major change that would put the US at odds with a large portion of the global community with little proof for improved outcomes. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a increased emphasis upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some childhood immunization guidelines in the US to become more similar to Denmark's approach, a country with universal health coverage and a number of inhabitants about the size of Wisconsin’s.

To date public appearances, she has continued to focus on immunizations – traditionally the responsibility of Dr. Prasad, head of the FDA’s CBER – instead of medication approval.

Doubts Over Qualifications

The appointee has no apparent track record in drug development, approval processes or leadership, which has been standard for past heads of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have the necessary background” for leading the CDER, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in running a sizeable institution. She has no expertise in industry regulation.”

Former heads of CBER would “understand regulatory frameworks and the underlying principles of drug development”, noted Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who ran CBER have had.”

The drug center has an immense workload at the agency, the former commissioner emphasized.

“The public just pays attention on the innovative therapies, but the generic drug division approves thousands of generic drugs. There is also a biologic copycat branch, OTC medication office and other areas, and all of those need to be looked after,” Dr. Woodcock said. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a significant administrative component to the job, which oversees in excess of 5,000 employees. “It’s a massive management job, if you perform it correctly,” she added.

Response and Controversial Policies

When asked about concerns about Dr. Høeg's qualifications and whether this assignment represents increased cooperation among agency officials on immunizations, a representative said that the “questions rely on inaccurate assumptions”.

“Her experience aligns with the functions of her position,” the official said, noting the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a controversial rapid therapy clearance system that allegedly troubled her preceding directors. “By what process are these therapies being chosen for this voucher program? Who makes the choices?” Dr. Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards laxer rules of all drugs, aside from vaccines.”

Established Past Work on Vaccines

Concerning immunizations, Høeg has a clearer, if troubling, past, Howard have noted. She released a analysis using non-validated public submissions to determine the rate of myocarditis following COVID-19 vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the new government encompassed revising regulations for recently developed shots and halting “unnecessary” immunizations, she said after the election on a online show. At the FDA, Høeg has allegedly floated the idea of excluding young men from obtaining COVID-19 vaccines.

“She is an complete dogmatist who starts off with her beliefs and tailors the evidence to fit the data in a very disingenuous, fraudulent fashion,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined fellow contrarians, {like|